Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Katsuyuki Hotta, Takashi Seto et al.|The Lancet Oncology|2019

Cited by 617